Bei Wang, Wen Xu, Yuxuan Cai, Kai Liu, Jiacheng Wu, Chong Guo and Chengfu Yuan* Pages 4107 - 4113 ( 7 )
Background: Long non-coding RNA (lncRNA) breast cancer anti-estrogen resistance 4 (BCAR4) is a characterized oncogenic lncRNA in different cancers. This review is dedicated to summarize various molecular mechanisms of BCAR4 and demonstrate that the biological functions exerted by BCAR4 are good entry points for therapy.
Methods: The molecular mechanism of BCAR4 acting on tumors is summarized by reviewing PubMed.
Results: The expression of lncRNA BCAR4 is abnormally increased in all kinds of tumors, including colorectal cancer, prostate cancer, bladder cancer, gastric cancer, chondrosarcoma, glioma, breast cancer, glioma, gastric cancer, liver cancer, cervical cancer, lung cancer, etc. Besides, BCAR4 mediates multiple processes involved in carcinogenesis, including proliferation, invasion, anti-apoptosis, migration.
Conclusion: BCAR4 may show great clinical value in this direction as a therapeutic cancer target.
Long non-coding RNA, BCAR4, cancer, biomarkers, prognosis, cancer.
College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002, College of Medical Science, China Three Gorges University, Yichang 443002